ATP III

The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) provides recommendations for cholesterol testing and management from the National Cholesterol Education Program (NCEP). It is similar to Adult. It focuses on the role of the clinical approach to prevention of coronary heart disease (CHD) and identifies low-density lipoprotein (LDL) as the primary target of cholesterol-lowering therapy.
The following content matched the glossary term:
ATP III

Mule G, Nardi E, Cottone S, et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med. 2005;257:503-513. The aim of our study was to analyse, in a wide group of essential hypertensive patients without diabetes mellitus, the influence of metabolic syndrome (MS) (defined according to the criteria laid down in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) on markers of preclinical cardiac, renal and retinal damage.

de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004;110:2494-2497. Metabolic syndrome (MetS) is defined by the Third Report of the Adult Treatment Panel (ATP III) using criteria easily applied by clinicians and researchers. There is no standard pediatric definition.

Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27:2444-2449. The prevalence of the metabolic syndrome is high among U.S. adults. Our purpose was to determine whether the prevalence of this syndrome has changed since 1988-1994.

Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359. The importance of treating patients with the metabolic syndrome-commonly referred to as the insulin resistance syndrome-for the purpose of preventing cardiovascular disease was highlighted in ATP III (the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults).